Literature DB >> 10673713

The promise of nucleic acid vaccines.

N P Restifo1, H Ying, L Hwang, W W Leitner.   

Abstract

Establishing the effective use of 'naked' nucleic acids as vaccines would undoubtedly be one of the most important advances in the history of vaccinology. While nucleic acids show much promise for use as vaccine vectors in experimental animals, not a single naked nucleic acid vector has been approved for use in humans. Indeed, data from human clinical trials is scant: nucleic acid vaccines have not been clearly demonstrated to have any convincing efficacy in the prevention or treatment of infectious disease or cancer. Here we illustrate possible mechanisms underlying effective nucleic acid vaccination. We focus on progress that has been made in the improvement of their function. Additionally, we identify promising new strategies and try to forecast future developments that could lead to the real success of nucleic acid vaccines in the prevention and treatment of human disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673713      PMCID: PMC2241736          DOI: 10.1038/sj.gt.3301117

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  32 in total

1.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

2.  Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

Authors:  W W Leitner; H Ying; D A Driver; T W Dubensky; N P Restifo
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

Review 3.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

4.  Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression.

Authors:  H L Davis; R G Whalen; B A Demeneix
Journal:  Hum Gene Ther       Date:  1993-04       Impact factor: 5.695

5.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

Authors:  Z Xiang; H C Ertl
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

6.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Antigen processing in vivo and the elicitation of primary CTL responses.

Authors:  N P Restifo; I Bacík; K R Irvine; J W Yewdell; B J McCabe; R W Anderson; L C Eisenlohr; S A Rosenberg; J R Bennink
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

8.  The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer.

Authors:  J R Ellis; P J Keating; J Baird; E F Hounsell; D V Renouf; M Rowe; D Hopkins; M F Duggan-Keen; J S Bartholomew; L S Young
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

9.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Authors:  V Bronte; K Tsung; J B Rao; P W Chen; M Wang; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

10.  Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.

Authors:  B R Minev; B J McFarland; P J Spiess; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

View more
  35 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Effective and robust plasmid topology analysis and the subsequent characterization of the plasmid isoforms thereby observed.

Authors:  Michael J Molloy; Valerie S Hall; Susannah I Bailey; Katharine J Griffin; Jim Faulkner; Mark Uden
Journal:  Nucleic Acids Res       Date:  2004-09-09       Impact factor: 16.971

3.  Ligands located within a cholesterol domain enhance gene delivery to the target tissue.

Authors:  Long Xu; Jamie Betker; Hao Yin; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2012-03-09       Impact factor: 9.776

Review 4.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

Review 5.  Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.

Authors:  Long Xu; Thomas Anchordoquy
Journal:  J Pharm Sci       Date:  2011-01       Impact factor: 3.534

6.  Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.

Authors:  Anne C Moore; Wing-pui Kong; Bimal K Chakrabarti; Gary J Nabel
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 7.  Gene therapy for autoimmune disorders.

Authors:  C H Evans; S C Ghivizzani; T J Oligino; P D Robbins
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

8.  MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells.

Authors:  J Mark Sloan; Michael H Kershaw; Christopher E Touloukian; Rejean Lapointe; Paul F Robbins; Nicholas P Restifo; Patrick Hwu
Journal:  Cancer Gene Ther       Date:  2002-11       Impact factor: 5.987

Review 9.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

10.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.